Ironwood Pharmaceuticals Inc (IRWD, Financial) is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
As of the latest available data, Ironwood Pharmaceuticals Inc has an outstanding share count of 156.03 million. Institutional ownership stands at 98.77 million shares, constituting 63.3% of the total shares. Meanwhile, insiders hold 9.27 million shares, accounting for 5.94% of the total share count.
Recent Market Performance and Ownership Trends
Ironwood Pharmaceuticals Inc experienced a decline of about 11.39% in its stock value over the past week. As of Sep 22 2023, the stock fell by 1.28%, contrasting / consistent with its three-month return of -15.55. A closer look reveals fluctuations in its market cap, which rose to $1.66 billion in the most recent quarter from $1.63 billion in the preceding one. This volatility has sparked keen interest in the company's ownership trends.
Institutional Ownership and Key Players
Ironwood Pharmaceuticals Inc's institutional ownership history reveals the levels of trust and confidence that major players have in the company's future. As of 2023-08-31, Ironwood Pharmaceuticals Inc's institutional ownership level is 63.3%, down from institutional ownership of 66.17% as of 2023-05-31 and down from institutional ownership of 92.78% from a year ago.
Among the most significant stakeholders , the top fund managers owning chunks of Ironwood Pharmaceuticals Inc's stock are HOTCHKIS & WILEY (Trades, Portfolio), First Eagle Investment (Trades, Portfolio), and Jefferies Group (Trades, Portfolio), with 0.64%, 0.38%, and 0.21% of shares outstanding respectively.
Delving into Earnings: Past and Future
Financial performance remains a cornerstone of investment decisions. Over the past three years, Ironwood Pharmaceuticals Inc's Ebitda growth averaged 29.4% per year, which is better than 75.93% of 889 companies in the Drug Manufacturers industry. This growth extends to the five-year marker, with a growth of 0% .
Insider Ownership and Activities
Insider ownership offers insights into the convictions of the company's board directors and C-level employees. Ironwood Pharmaceuticals Inc's insider ownership is approximately 5.94% as of 2023-08-31, compared to insider ownership of 5.77% from a year ago, reflecting the increased faith of those intimately familiar with the company's operations.
Next Steps
In the ever-evolving realm of stocks, understanding the nuances of ownership and earnings is critical. Ironwood Pharmaceuticals Inc's recent dip is a case study in how major players react to market shifts, and their movements offer crucial insights for potential investors. As always, a holistic view, combining both past performance and future projections, remains key to sound investment decisions.
Screen for stocks with high Insider Cluster Buys using the following page: https://www.gurufocus.com/insider/cluster.
